METASTATIC HEPATOCELLULAR CARCINOMA
Clinical trials for METASTATIC HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough liver cancer gene mutation
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to see if the combination is safe and works better than cabozantinib alone. About 92 adults with liver cancer tha…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
Can radiation kickstart the immune system against stubborn cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are getting worse despite immunotherapy. It tests whether giving focused radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiation wh…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New hope for Hard-to-Treat cancers: first human trial of TYRA-430 begins
Disease control Recruiting nowThis early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for si…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
Could a painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis study tests whether adding celecoxib (a painkiller) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The go…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment that takes a person's own immune cells, modifies them in a lab to better recognize and attack cancer cells, and then returns them to the patient. It is for adults with advanced solid tumors that express a protein called GPC3, such as l…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-B2033, alone or with other cancer medicines, in people with advanced liver, stomach, lung, or rare germ cell tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for advanced liver cancer: targeted drug trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called ALN-BCAT, given alone or with an immunotherapy (pembrolizumab), in people with advanced liver cancer that has spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 158 adults whose …
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
Electric field therapy worn like a vest shows promise against tough cancers
Disease control Recruiting nowThis early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope for liver cancer: combo therapy tested after first treatment fails
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (atezolizumab) to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed and has already been treated with …
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New hope for liver cancer: pfizer launches trial of PF-08634404
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Could less be more? new study tests lower cancer drug doses to cut side effects
Disease control Recruiting nowThis study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: METASTATIC HEPATOCELLULAR CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 03:56 UTC